Preferred Label : Proprotein Convertase 9;

MeSH definition : A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.;

MeSH synonym : Convertase 9, Proprotein; Neural Apoptosis-Regulated Convertase 1; Neural Apoptosis Regulated Convertase 1; NARC-1 Protein; NARC 1 Protein; Proprotein Convertase, Subtilisin-Kexin Type 9; Proprotein Convertase, Subtilisin Kexin Type 9;

Registry Number MeSH : EC 3.4.21.-;

Details


Main resources

You can consult :

A proprotein convertase that is essential for CHOLESTEROL homeostasis. It binds to and is required for the lysosomal degradation of the LDL RECEPTOR (LDLR); the VLDL receptor, and the APOLIPOPROTEIN E RECEPTOR. It also regulates neuronal APOPTOSIS.

https://pharmacomedicale.org/component/zoo/item/anti-pcsk9
2022
France
scientific and technical information
Proprotein Convertase 9

---
https://www.cochrane.org/fr/CD011748/VASC_inhibiteurs-de-la-pcsk9-pour-la-prevention-des-maladies-cardiovasculaires
2020
false
false
false
France
United Kingdom
Substance with proprotein convertase subtilisin/kexin type 9 inhibitor mechanism of action (substance)
Proprotein Convertase 9
treatment outcome
Substance with proprotein convertase subtilisin/kexin type 9 inhibitor mechanism of action (substance)
cholesterol, LDL
alirocumab
evolocumab
Evidence-Based medicine
review of literature
french abstract
cardiovascular diseases
cardiovascular prevention
antibodies, monoclonal

---
https://www.revmed.ch/RMS/2017/RMS-N-558/Inhibiteurs-de-la-PCSK9
2017
false
false
false
Switzerland
French
journal article
Proprotein Convertase 9
Proprotein Convertase 9
anticholesteremic agents
anticholesteremic agents
cardiovascular diseases
risk factors
cholesterol, LDL
At increased risk for cardiovascular event (finding)
hydroxymethylglutaryl-coa reductase inhibitors
hypercholesterolemia
Proprotein Convertase 9
mutation
alirocumab
evolocumab
PCSK9 protein, human
bococizumab
comparative effectiveness research
high serum cholesterol, familial
antibodies, monoclonal
serine endopeptidases
proprotein convertases
antibodies, monoclonal, humanized
hyperlipoproteinemia type ii

---
Nous contacter.
14/05/2024


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.